Inhibition of organic cation transporter 2 and 3 may be involved in the mechanism of the antidepressant-like action of berberine

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 49, Issue , 2014, Pages 1-6

  Sun, Siyuan ^a   Wang, Kai ^a   Lei, Hongmei ^a   Li, Liping ^a   Tu, Meijuan ^a   Zeng, Su ^a   Zhou, Hui ^a   Jiang, Huidi ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antidepressant; Berberine; Organic cation transporter 2; Organic cation transporter 3; Uptake 2

Indexed keywords

BERBERINE; MONOAMINE; NORADRENALIN; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; SEROTONIN; ANTIDEPRESSANT AGENT; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, HUMAN; SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 3;

ANIMAL CELL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENETIC TRANSFECTION; HUMAN; IC 50; MALE; MDCK CELL; MOUSE; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN UPTAKE; NORADRENERGIC SYSTEM; PROTEIN SYNTHESIS INHIBITION; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; CELL CULTURE; DOG; DRUG EFFECTS; MDCK CELL LINE; METABOLISM; SYNAPTOSOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BERBERINE; BRAIN; CELLS, CULTURED; DOGS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; NOREPINEPHRINE; ORGANIC CATION TRANSPORT PROTEINS; SEROTONIN; SYNAPTOSOMES;

EID: 84888769489     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.11.005     Document Type: Article

References (39)

1. Amphoux A., Vialou V., Drescher E., Bruss M., La Cour C.M., Rochat C., et al. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology 2006, 50:941-952.
2. Bacq A., Balasse L., Biala G., Guiard B., Gardier A.M., Schinkel A., et al. Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatr 2012, 17:926-939.
3. Baganz N., Horton R., Martin K., Holmes A., Daws L.C. Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun. J Neurosci 2010, 30:15185-15195.
4. Baganz N.L., Horton R.E., Calderon A.S., Owens W.A., Munn J.L., Watts L.T., et al. Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. P Natl Acad Sci USA 2008, 105:18976-18981.
5. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7:137-151.
6. Cui M., Aras R., Christian W.V., Rappold P.M., Hatwar M., Panza J., et al. The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. P Natl Acad Sci USA 2009, 106:8043-8048.
7. Daws L.C. Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 2009, 121:89-99.
8. Daws L.C., Koek W., Mitchell N.C. Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders. ACS Chem Neurosci 2013, 4:16-21.
9. Duan H.C., Wang J. Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther 2010, 335:743-753.
10. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther. 2001, 91:35-62.
11. Engel K., Zhou M.Y., Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 2004, 279:50042-50049.
12. Gasser P.J., Lowry C.A., Orchinik M. Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci 2006, 26:8758-8766.
13. Hirschfeld R.M.A. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatr 2000, 61:4-6.
14. Horton R.E., Apple D.M., Owens W.A., Baganz N.L., Cano S., Mitchell N.C., et al. Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression. J Neurosci 2013, 33:10534-10543.
15. Hu Y., Ehli E.A., Hudziak J.J., Davies G.E. Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region. Pharmacogenomics J 2012, 12:372-378.
16. Ivanovska N., Philipov S. Study on the anti-inflammatory action of Berberis vulgaris root extract, alkaloid fractions and pure alkaloids. Int J Immunopharmacol 1996, 18:553-561.
17. Kanazawa I. Short Review on Monoamine-Oxidase and Its Inhibitors. Eur Neurol 1994, 34:36-39.
18. Koepsell H., Lips K., Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007, 24:1227-1251.
19. Kong L.D., Cheng C.H.K., Tan R.X. Monoamine oxidase inhibitors from rhizoma of Coptis chinensis. Planta Med 2001, 67:74-76.
20. Kulkarni S.K., Dhir A. Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant activity of berberine chloride. Eur J Pharmacol 2007, 569:77-83.
21. Kulkarni S.K., Dhir A. On the mechanism of antidepressant-like action of berberine chloride. Eur J Pharmacol 2008, 589:163-172.
22. Kulkarni S.K., Dhir A. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 2010, 24:317-324.
23. Lee Y.S., Kim W.S., Kim K.H., Yoon M.J., Cho H.J., Shen Y., et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006, 55:2256-2264.
24. Mooney J.J., Samson J.A., Hennen J., Pappalardo K., McHale N., Alpert J., et al. Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3). J Psychiatr Res 2008, 42:605-611.
25. Nies A.T., Herrmann E., Brom M., Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn-Schmiedeberg's Arch Pharmacol 2008, 376:449-461.
26. Owens M.J., Krulewicz S., Simon J.S., Sheehan D.V., Thase M.E., Carpenter D.J., et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacol 2008, 33:3201-3212.
27. Park H., Kim M.S., Jeon B.H., Kim T.K., Kim Y.M., Ahnn J., et al. Antimalarial activity of herbal extracts used in traditional medicine in Korea. Biol Pharm Bull 2003, 26:1623-1624.
28. Peng W.H., Hsieh M.T., Wu C.R. Effect of long-term administration of berberine on scopolamine-induced amnesia in rats. Jpn J Pharmacol 1997, 74:261-266.
29. Peng W.H., Lo K.L., Lee Y.H., Hung T.H., Lin Y.C. Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice. Life Sci 2007, 81:933-938.
30. Peng W.H., Wu C.R., Chen C.S., Chen C.F., Leu Z.C., Hsieh M.T. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors. Life Sci 2004, 75:2451-2462.
31. Rabbani G.H., Butler T., Knight J., Sanyal S.C., Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia-coli and Vibrio-cholerae. J Infect Dis 1987, 155:979-984.
32. Rahman Z., Ring R.H., Young K., Platt B., Lin Q., Schechter L.E., et al. Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine. Brain Res 2008, 1203:68-78.
33. Rappold P.M., Cui M., Chesser A.S., Tibbett J., Grima J.C., Duan L.H., et al. Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. P Natl Acad Sci USA 2011, 108:20766-20771.
34. Schmeller T., LatzBruning B., Wink M. Biochemical activities of berberine, palmatine and sanguinarine mediating chemical defence against microorganisms and herbivores. Phytochemistry 1997, 44:257-266.
35. Torres G.E., Gainetdinov R.R., Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 2003, 4:13-25.
36. Tu M., Sun S., Wang K., Peng X., Wang R., Li L., et al. Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important role in its hepatotoxicity. Toxicology 2013, 311:225-230.
37. Wultsch T., Grimberg G., Schmitt A., Painsipp E., Wetzstein H., Breitenkamp A.F.S., et al. Decreased anxiety in mice lacking the organic cation transporter 3. J Neural Transm 2009, 116:689-697.
38. Zhu H.J., Appel D.I., Grundemann D., Markowitz J.S. Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem 2010, 114:142-149.
39. Zhu H.J., Appel D.I., Grundemann D., Richelson E., Markowitz J.S. Evaluation of organic cation transporter 3 (SLC22A3) inhibition as a potential mechanism of antidepressant action. Pharmacol Res 2012, 65:491-496.